Ucb Biopharma Sprl

Ucb Pharma, S.a.

Ucbbiopharma Srl

Thomas Allen Ceska

Alistair James Henry

Ralph Adams

Kerry Louise Tyson

Helene Margaret Finney

Bryan John Smith

Jiye Shi

Lara Kevorkian

Xiaofeng Liu

Kaushik Sarkar

Paul Alan Atherfold

Anna Marie Davies

James Michael McDonnell

Brian John Sutton

Marta Katarzyna Westwood

Alistar James Henry

Jijye Shi

The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

Anti-IgE antibodies

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Antibodies specific to FCRN

The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc&#x3b5;RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair&#xae;). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C&#x3b5;2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C&#x3b5;2 domain of IgE) and/or the ability to disassociate IgE from the Fc&#x3b5;RI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the Fc&#x3b5;RI receptor).

Antibodies specific to FcRn

The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.

Methods of treating an IL-17A mediated pathological condition

Antibodies specific to IL-17A and IL-17F

The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.

Growing community of inventors

Slough, United Kingdom

Thomas Allen Ceska